Response to Shiga toxin-1, with and without lipopolysaccharide, in a primate model of hemolytic uremic syndrome

American Journal of Nephrology

Volumn 21, Issue 5, 2001, Pages 420-425

  Siegler, Richard L ^a   Pysher, Theodore J ^b   Lou, Randall ^a   Tesh, Vernon L ^d   Taylor Jr , Fletcher B ^c  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b PRIMARY CHILDREN'S MEDICAL CENTER   (United States)

^c OKLAHOMA MEDICAL RESEARCH FOUNDATION   (United States)

^d TEXAS A AND M UNIVERSITY   (United States)

Author keywords

Escherichia coli; Hemolytic uremic syndrome; Lipopolysaccharide; Shiga toxin

Indexed keywords

INTERLEUKIN 6; INTERLEUKIN 8; LIPOPOLYSACCHARIDE; SHIGA TOXIN; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; VEROTOXIN 1;

ACUTE KIDNEY FAILURE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BABOON; CLINICAL FEATURE; CONTROLLED STUDY; CYTOKINE RELEASE; DISEASE COURSE; DISEASE MODEL; ESCHERICHIA COLI; HEMOLYTIC UREMIC SYNDROME; MALE; NONHUMAN; PATHOGENESIS; PRIMATE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN URINE LEVEL;

ANIMALS; CYTOKINES; DISEASE MODELS, ANIMAL; DRUG SYNERGISM; ENDOTOXINS; ESCHERICHIA COLI; HEMOLYTIC-UREMIC SYNDROME; INJECTIONS, INTRAVENOUS; KIDNEY; KIDNEY FAILURE, ACUTE; MALE; PAPIO; RENAL CIRCULATION; SHIGA-LIKE TOXIN I; STATISTICS, NONPARAMETRIC; THROMBOCYTOPENIA;

EID: 0035743193     PISSN: 02508095     EISSN: None     Source Type: Journal    
DOI: 10.1159/000046288     Document Type: Article

References (31)

1. High incidence of serum antibodies to Escherichia coli lipopolysaccharide in children with hemolytic-uremic syndrome
2. Serological identification of Escherichia coli O157:H7 infection in haemolytic uraemic syndrome
3. Shriniwas: Serum antibodies to verotoxin-producing Escherichia coli (VTEC) strains in patients with haemolytic uraemic syndrome
4. The hemolytic uremic syndrome
5. Characterization of the baboon responses to Shiga-like toxin (descriptive study of a new primate model of toxic responses to Stx-1)
6. Response to single and divided doses of Shiga toxin-1 in a primate model of hemolytic uremic syndrome
7. Purified shiga-like toxins induce expression of proinflammatory cytokines from murine peritoneal macrophages
8. Specific interaction of Escherichia coli O157:H7-derived Shiga-like toxin II with human renal endothelial cells
9. The role of lipopolysaccharide and Shiga-like toxin in a mouse model of Escherichia coli O157:H7 infection
10. Shiga toxin-associated hemolytic uremic syndrome: Combined cytotoxic effects of Shiga toxin and lipopolysaccharide (endotoxin) on human vascular endothelial cells in vitro
11. Hemoglobin enhances the production of tissue factor by endothelial cells in response to bacterial endotoxin
12. Sequence of glomerular changes in experimental endotoxemia: A possible model of hemolytic uremic syndrome
13. Stimulated kidney tubular epithelial cells express membrane associated and secreted TNFα
14. Cytokine response to Shiga toxins
15. Effects of verocytotoxin-1 on nonadherent human monocytes: Binding characteristics, protein synthesis, and induction of cytokine release
16. Plasma and urinary cytokines in the childhood hemolytic uremic syndrome (HUS)
17. Cytokines in childhood hemolytic uremic syndrome and thrombotic thrombocytopenic purpura
18. Tumor necrosis factor concentrations in hemolytic uremic syndrome patients and children with bloody diarrhea in Argentina
19. Inflammatory mediators in Escherichia coli O157:H7 hemorrhagic colitis and hemolytic-uremic syndrome
20. Recombinant tumor necrosis factor induces procoagulant activity in cultured human vascular endothelium: Characterization and comparison with the actions of interleukin 1
21. Production of soluble ICAM-1 from human endothelial cells induced by IL-1β and TNF-α
22. Tumor necrosis factor induces von Willebrand factor release in healthy humans
23. Effects of TNFα on verocytotoxin cytotoxicity in purified human glomerular microvascular endothelial cells
24. Tumor necrosis factor-α and lipopolysaccharide induce apoptotic cell death in bovine glomerular endothelial cells
25. Interleukin-8 and poly-morphoneutrophil leucocyte activation in hemolytic uremic syndrome of childhood
26. Monocyte chemoattractant protein-1 and interleukin-8 levels in urine and serum of patients with hemolytic uremic syndrome
27. In vivo modulation of coagulation and fibrinolysis by recombinant glycosylated human interleukin-6 in baboons
28. Elimination of interleukin 6 attenuates coagulation activation in experimental endotoxemia in chimpanzees
29. Fibrin degradation product D-dimer induces the synthesis and release of biologically active IL-1β, IL-6 and plasminogen activator inhibitors from monocytes in vitro
30. Pathogenesis, treatment, and therapeutic trials in hemolytic uremic syndrome